Nukleofilní substituce na akridinu - možný viník za interakci akridinu s prionovým proteinem

Abstract

Covalent modification of lysine residue side chains in the hydrophobic core of prion protein aggregates could explain the discrepancy between the ability of the acridine drug quinacrine to reduce efficiently the incidence of prion protein in cell culture and its weak prion binding affinity